Porton Pharma Solutions released its 2026 interim report, with net profit attributable to the parent company at negative 224 million yuan, swinging from profit to loss and down 251 million yuan from the same period last year, a year-on-year decline of 928.55 percent. The company's total operating revenue was 1.79 billion yuan, and net cash inflow from operating activities was 306 million yuan. The latest gross margin was 32.23 percent, return on equity was negative 4.52 percent, and diluted earnings per share was negative 0.41 yuan.
Porton Fine Chemicals LtdReports net loss of 224 million yuan, swinging from profit to loss with a 928.55% decline.